Giant Cell Tumour of Bone
Orthopaedics · Bone Tumours · lean revision notes
Giant Cell Tumour of Bone
Giant cell tumour (GCT), or osteoclastoma, is a locally aggressive, benign but unpredictable primary bone tumour arising from osteoclast-like giant cells and their mononuclear stromal precursors. It is a darling of NEET PG because of its classic epiphyseal-eccentric location, "soap-bubble" radiology, Campanacci grading, and the newly tested role of denosumab. Master the age, site, radiology, and management triad and you have most of its marks.
Definition & basic concept
GCT is a benign but locally aggressive tumour of bone characterised histologically by abundant multinucleated osteoclast-type giant cells evenly distributed amid a background of mononuclear stromal cells. The crucial point — repeatedly examined — is that the neoplastic cell is the mononuclear stromal cell, NOT the giant cell. The giant cells are reactive osteoclasts recruited by the stromal cells.
High-yield: The neoplastic (proliferating) component of GCT is the mononuclear stromal cell; the giant cells are non-neoplastic, reactive osteoclasts. This is one of the most frequently asked one-liners.
A landmark molecular discovery is the driver mutation: a recurrent H3F3A (histone H3.3) G34W mutation in the stromal cells, now used immunohistochemically (H3.3 G34W antibody) to confirm the diagnosis and differentiate GCT from mimics.
The stromal cells over-express RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand), which recruits and activates osteoclast precursors via RANK → drives the osteolysis. This RANKL pathway is precisely what denosumab (anti-RANKL monoclonal antibody) targets — explaining its therapeutic role.
Epidemiology — the classic profile
| Feature | Typical finding |
|---|---|
| Age | 20–40 years (skeletally mature; after physeal closure) |
| Sex | Slight female predominance |
| Frequency | ~5% of all primary bone tumours; ~20% of benign bone tumours |
| Commonest sites | Distal femur > proximal tibia (around the knee ~50–60%), distal radius, proximal humerus, sacrum |
| Spine | Sacrum most common spinal site; vertebral body involvement |
| Multiplicity | Usually solitary; multicentric GCT rare (think hyperparathyroidism / Paget mimics) |
High-yield: GCT is a tumour of the skeletally mature adult — it does NOT typically occur before epiphyseal fusion. In children with open physes, an epiphyseal lytic lesion is more likely chondroblastoma, not GCT.
A frequently tested twist: in the immature skeleton, GCT-equivalent lesions are rare and instead occupy the metaphysis. Around the knee remains the favourite exam site.
Pathology
Gross: Soft, fleshy, reddish-brown tumour (haemorrhagic) with areas of necrosis and cystic/haemorrhagic degeneration. May expand and thin the overlying cortex, occasionally breaching it with a thin reactive shell.
Microscopy (classic triad):
- Multinucleated giant cells — large, with many (sometimes 50–100) nuclei, uniformly distributed.
- Mononuclear stromal cells — round-to-spindle, the true neoplastic cells; nuclei resemble those of the giant cells (key clue that they are the same lineage).
- Scant matrix; areas of haemorrhage, haemosiderin, foam cells, and reactive bone at the periphery.
High-yield: Mitoses may be present in the stromal cells — but mitotic activity does NOT predict malignancy or behaviour in GCT. Atypical mitoses, however, should raise suspicion of a true malignant GCT/sarcoma.
The presence of vascular invasion (tumour thrombi in vessels) can be seen even in benign GCT and explains the capacity for benign pulmonary "metastases."
Clinical features
- Pain around a joint (commonly the knee) — dull, progressive.
- Swelling and localised tenderness; joint effusion if juxta-articular.
- Restricted joint movement; occasionally a pathological fracture is the presenting event.
- A characteristic but soft sign: "egg-shell crackling" on palpation when the cortex is markedly thinned.
- Long history (months) of insidious symptoms; constitutional symptoms are absent unless malignant transformation.
Stepwise clinical approach: persistent peri-articular knee pain/swelling in a 20–40 yr adult → plain radiograph (eccentric epiphyseal lytic lesion) → MRI for extent/soft-tissue → biopsy for confirmation → stage (Campanacci) → plan surgery.
High-yield: Classic exam vignette = "30-year-old with knee pain; X-ray shows an eccentric, expansile, lytic lesion in the epiphysis of distal femur extending to the articular surface, no surrounding sclerosis, no periosteal reaction." → Giant cell tumour.
Radiology — the signature
Plain radiograph is the single most useful first investigation and is highly characteristic:
| Radiological feature | Description |
|---|---|
| Location | Epiphyseal & eccentric, extending up to (subchondral) the articular surface |
| Lucency | Purely lytic / osteolytic, expansile |
| Matrix | No matrix mineralisation / no calcification (helps exclude chondral/osseous tumours) |
| Margin | Geographic, narrow zone of transition, usually non-sclerotic rim |
| Periosteum | No periosteal reaction typically (unlike aggressive malignancies) |
| Pattern | "Soap-bubble" appearance (trabeculated, multiloculated look — actually ridges in the wall, not true septa) |
| Cortex | Thinned, expanded; may be breached with soft-tissue extension in aggressive lesions |
High-yield: GCT = eccentric, epiphyseal, lytic, soap-bubble lesion reaching the articular surface with NO matrix calcification and NO periosteal reaction. Lack of a sclerotic rim differentiates it from many benign mimics.
MRI is the investigation of choice for staging/extent — defines marrow involvement, soft-tissue extension, and proximity to neurovascular structures, and detects associated secondary aneurysmal bone cyst (ABC) change (fluid–fluid levels). CT helps assess cortical breach and is useful in sacral/pelvic lesions.
A useful caveat: GCT can show fluid–fluid levels because of secondary ABC formation — do not be misled into calling it a primary ABC.
Campanacci radiological grading
The Campanacci grading is a favourite MCQ. It is based on radiographic appearance and predicts aggressiveness:
| Grade | Description |
|---|---|
| Grade I (latent/quiescent) | Well-marginated lesion, intact cortex, thin reactive bony margin |
| Grade II (active) | Relatively well-defined margins but no sclerotic rim; cortex thinned and expanded but intact |
| Grade III (aggressive) | Indistinct borders, cortical destruction, soft-tissue extension/mass |
High-yield: Campanacci grade does NOT reliably correlate with histology or with risk of recurrence/metastasis. It guides surgical aggressiveness but is not prognostic for malignant transformation. (Histologically GCT is not graded the way other tumours are — historically Jaffe grading existed but is abandoned because grade did not predict behaviour.)
The older Enneking staging (for benign tumours: latent S1, active S2, aggressive S3) is sometimes asked alongside Campanacci.
Diagnosis & investigation of choice
Stepwise: Clinical suspicion → Plain radiograph (first/best initial) → MRI (best for local staging) → Chest CT (to screen for pulmonary "benign metastases") → Biopsy (confirmatory / gold standard).
- Biopsy is the definitive confirmatory step before definitive surgery (image-guided core or open biopsy along planned resection line).
- IHC: H3.3 G34W positivity in mononuclear stromal cells supports diagnosis and excludes giant-cell-rich mimics.
- Serum calcium/PTH if multicentric — to exclude brown tumour of hyperparathyroidism, the great GCT mimic.
High-yield: Best initial investigation = plain X-ray; best for local extent/staging = MRI; confirmatory = biopsy/histopathology. Always image the chest because GCT can produce histologically benign pulmonary metastases (~1–4%).
Management — drug & surgery of choice
Treatment is primarily surgical, individualised by Campanacci grade, location, and joint involvement.
1. Intralesional curettage + adjuvant + filling (treatment of choice for most appendicular GCT — Grades I/II and many III):
- Extended/aggressive curettage with a high-speed burr to clear microscopic disease.
- Local adjuvants to reduce recurrence: phenol, hydrogen peroxide, liquid nitrogen (cryotherapy), or argon beam; thermal effect of PMMA (bone cement) polymerisation adds local kill.
- Defect filling: PMMA bone cement (preferred — allows early weight-bearing, the exothermic reaction kills residual cells, and recurrence is easier to detect on X-ray) or bone graft.
High-yield: Extended curettage + adjuvant + PMMA cementing is the standard of care for most GCT; cement is favoured over bone graft because of its thermal tumoricidal effect and the ease of detecting recurrence radiologically.
2. Wide / en-bloc resection — for extensively destructive Grade III lesions, expendable bones (distal ulna, proximal fibula, rib), recurrent disease, or where curettage cannot preserve the joint. Reconstruction with allograft, endoprosthesis, or arthrodesis as required.
3. Denosumab (anti-RANKL monoclonal antibody) — a heavily examined modern addition:
- Mechanism: binds RANKL → blocks osteoclast formation/activity → halts osteolysis and induces new bone formation around the tumour.
- Indications: unresectable/inoperable GCT (e.g., sacrum, spine, large pelvic lesions), to downstage before surgery (makes curettage feasible, ossifies the rim), and in metastatic/recurrent disease.
- Caution: It controls but may not cure; recurrence on stopping the drug, plus adverse effects — osteonecrosis of the jaw, hypocalcaemia, atypical femoral fractures, and concern over malignant transformation in rare cases.
4. Radiotherapy — reserved for surgically inaccessible lesions (axial/sacral) where surgery and denosumab are unsuitable, because of the risk of radiation-induced malignant transformation/sarcoma.
5. Bisphosphonates — adjunctive anti-osteoclast role, weaker evidence than denosumab.
High-yield: Denosumab targets RANKL; its key examinable toxicities are osteonecrosis of the jaw and hypocalcaemia. Radiotherapy is avoided when possible because of post-radiation sarcoma risk.
Complications
- Local recurrence — the dominant problem: ~10–25% after extended curettage (higher with simple curettage, ~40–50%), usually within 2–3 years. Distal radius and aggressive Grade III lesions recur more.
- Pathological fracture through the weakened cortex.
- Benign pulmonary metastases — histologically benign deposits in the lung in ~1–4% of cases; despite being "benign," they can occasionally be fatal but many remain stable or regress.
- Malignant transformation (~1–3%):
- Primary malignant GCT — sarcomatous areas coexisting with benign GCT at presentation.
- Secondary malignant GCT — sarcoma arising at a previously treated GCT site, classically after radiotherapy (latency years).
- Joint destruction/secondary osteoarthritis; surgical morbidity (infection, cement-related issues, hardware failure).
High-yield: GCT can give histologically benign lung metastases — a paradox loved by examiners. Malignant transformation is most associated with prior radiotherapy (secondary malignant GCT).
Key differential diagnoses
Several "giant-cell-rich" lesions mimic GCT. Distinguishing them is high-yield:
| Lesion | Distinguishing point vs GCT |
|---|---|
| Chondroblastoma | Child/adolescent, open physis, epiphyseal but with calcification/matrix; "chicken-wire" calcification on histology |
| Aneurysmal bone cyst (ABC) | Younger, metaphyseal, eccentric, fluid–fluid levels; may coexist with GCT secondarily |
| Brown tumour (hyperparathyroidism) | Identical histology (giant cells); look for raised PTH/calcium, subperiosteal resorption, multiplicity |
| Giant cell reparative granuloma | Hands/feet, jaw; more reactive bone, fewer evenly spread giant cells |
| Telangiectatic osteosarcoma | Aggressive, destructive, malignant cells, osteoid; can mimic lytic GCT |
| Non-ossifying fibroma / fibrous cortical defect | Metaphyseal, cortical, sclerotic margin, asymptomatic |
| Osteoblastoma / osteoid osteoma | Different age/site, nidus, nocturnal pain relieved by NSAIDs (osteoid osteoma) |
| Chondromyxoid fibroma | Metaphyseal, eccentric, lobulated |
High-yield: The single most important histological mimic is the brown tumour of hyperparathyroidism — always check serum calcium and PTH, especially if GCT appears multicentric.
Quick site-based discriminator (around the knee):
- Epiphysis + skeletally mature + lytic, no matrix → GCT
- Epiphysis + open physis + calcified matrix → Chondroblastoma
- Metaphysis + fluid levels + young → ABC
- Metaphysis + sunburst/Codman triangle + osteoid → Osteosarcoma
Mnemonics & named facts
- "GCT — Grown-up's Soap-bubble at the Epiphysis" → adult, soap-bubble, epiphyseal.
- Eponym/alternate name: Osteoclastoma.
- RANKL → denosumab link; H3F3A (H3.3) G34W mutation.
- Adjuvant mnemonic "PHACE" for local adjuvants: Phenol, Hydrogen peroxide, Argon beam, Cryotherapy (liquid nitrogen), Exothermic cement.
Recently asked / exam angle
NEET PG and INI-CET style questions on GCT cluster around a few reliable themes:
- "Which is the neoplastic cell in GCT?" → mononuclear stromal cell (not the giant cell). Recurrent single-best-answer.
- Radiology image questions: eccentric epiphyseal soap-bubble lytic lesion in distal femur/proximal tibia reaching the articular surface → identify GCT; identify no periosteal reaction / no matrix.
- Campanacci grading — match grade descriptions; remember it is radiological and does NOT predict malignancy.
- Denosumab — mechanism (anti-RANKL), indication (unresectable/sacral GCT, downstaging), and adverse effects (ONJ, hypocalcaemia) — a modern high-yield area.
- Treatment of choice — extended curettage + adjuvant + PMMA cement; why cement over graft (thermal kill + recurrence monitoring).
- Benign pulmonary metastasis — true/false and assertion-reason style.
- Malignant transformation after radiotherapy (secondary malignant GCT).
- Mimic spotting: chondroblastoma (child, epiphysis, calcified) vs GCT (adult, epiphysis, lytic); brown tumour with deranged PTH.
- Molecular: H3.3 G34W mutation/IHC — increasingly appearing in pathology-leaning papers.
Rapid revision
- GCT = benign but locally aggressive osteoclastoma; neoplastic cell is the mononuclear stromal cell.
- Age 20–40 yrs, skeletally mature, slight female predilection.
- Site: epiphyseal + eccentric, commonest around the knee (distal femur > proximal tibia); also distal radius, sacrum.
- X-ray: lytic, expansile, soap-bubble, reaches articular surface, NO matrix, NO periosteal reaction, non-sclerotic margin.
- MRI = best for local staging; biopsy = confirmatory; screen chest for benign lung mets.
- Campanacci I–III is radiological and does not predict malignancy or recurrence.
- Treatment of choice = extended curettage + adjuvant (phenol/H₂O₂/cryo) + PMMA cement; en-bloc resection for aggressive/recurrent/expendable bone.
- Denosumab = anti-RANKL, for unresectable/sacral GCT and downstaging; toxicities = ONJ, hypocalcaemia.
- Avoid radiotherapy where possible → risk of secondary malignant transformation (sarcoma).
- Recurrence ~10–25% within 2–3 years; can give histologically benign pulmonary metastases.
- Key histological mimic = brown tumour of hyperparathyroidism — check PTH/calcium, especially if multicentric.
- Child + epiphysis + calcified lesion = chondroblastoma, not GCT; driver mutation in GCT = H3F3A G34W.